Almirall
CorporateInvestors

Almirall will reserve shares from its stock market listing for company employees

Barcelona, 21 May 2007.- Laboratorios Almirall, S.A., a Spanish independent pharmaceutical company, announced today that, as part of its plan to apply for a listing of its shares on the Spanish Stock Exchange, it intends to reserve part of the associated equity offering under preferential conditions for employees of the company and its subsidiaries.

With this decision, Almirall wants to recognize its employees’ commitment by providing them with the possibility of participating directly in the company’s equity. The terms and conditions of this tranche, together with other questions relating to the Offering, will be described in detail in the Folleto (Information Prospectus) of the Offering which will be registered by the Comisión Nacional del Mercado de Valores (Spanish Stock Market Commission).

 

About Almirall

Almirall, a leading company committed to health, is a consolidated international pharmaceutical company that researches, develops and commercialises its own R&D and licensed drugs with the aim of improving people’s health and quality of life.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD, psoriasis, rheumatoid arthritis and multiple sclerosis.

Almirall is currently present in over 80 countries. The company has direct presence in Europe and Latin America via affiliates in France, Germany, Italy, Portugal, Belgium and Mexico.

For further information:

Ketchum/SEIS

Tony Noel / Mónica Escusa

tony.noel@ketchum.com

monica.escusa@ketchum.com

Tel.: +34 91 788 32 00.- Fax: +34 91 788 32 99

 

 

Note

 

This document is a press release and not a prospectus. Investors should not therefore acquire or apply for any shares or other securities mentioned herein without having previously consulted the information containedwithintheofficial prospectus relating to the flotation ofcompany shares on theSpanishstock exchanges, which will be published by the company in due course. Copies of the prospectus will be available at the registered offices of the Company once they have been published.

 

This document should in no way be construed as an offer or invitation to treat, nor does it represent an offer to buy or subscribe to shares in the Company. Likewise, the contents of this document and the fact that it has been distributed must not be used as, or form the basis for, any kind of contract or decision to invest and do not constitute any recommendation as regards the securities of the Company.

 

This communication is intended solely for people living outside the United Kingdom and may not be used by anybody living within that country.

The information contained herein does not constitute an offer of securities in the United States. Offers and sales of securities in the United States may not be made absent registration under the U.S. Securities Act of 1933, as amended, or an applicable exemption therefrom. This document does not solicit money, securities or any other type of consideration, and, if any money, securities or other type of consideration is sent in response hereto, it will not be accepted.

 

Finally, neither this document nor any copy thereof may be taken or transmitted to the United States of America, Canada, Australia or Japan or be distributed, either directly or indirectly, in the United States of America, Canada, Australia or Japan or given to residents of any of these countries.

 

Press release

View Online